MX2020004914A - Metodos y composiciones para tratar el cancer mediante la modificacion de multiples brazos del sistema inmunitario. - Google Patents

Metodos y composiciones para tratar el cancer mediante la modificacion de multiples brazos del sistema inmunitario.

Info

Publication number
MX2020004914A
MX2020004914A MX2020004914A MX2020004914A MX2020004914A MX 2020004914 A MX2020004914 A MX 2020004914A MX 2020004914 A MX2020004914 A MX 2020004914A MX 2020004914 A MX2020004914 A MX 2020004914A MX 2020004914 A MX2020004914 A MX 2020004914A
Authority
MX
Mexico
Prior art keywords
compositions
methods
immune system
multiple arms
treating cancer
Prior art date
Application number
MX2020004914A
Other languages
English (en)
Inventor
Vimal D Mehta
Luca Rastelli
Deborah H Charych
Krishnan Nandabalan
Jonathan Zalevsky
John Macdougall
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of MX2020004914A publication Critical patent/MX2020004914A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se proporcionan métodos y composiciones para terapias contra el cáncer. Las combinaciones modifican múltiples brazos del sistema inmunitario, incluido un modificador de inmunidad innata, un inhibidor del punto de control inmunitario y un estimulador de células T, para tratar el cáncer.
MX2020004914A 2017-11-13 2018-11-13 Metodos y composiciones para tratar el cancer mediante la modificacion de multiples brazos del sistema inmunitario. MX2020004914A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762584999P 2017-11-13 2017-11-13
US201862629473P 2018-02-12 2018-02-12
US201862679576P 2018-06-01 2018-06-01
US201862712457P 2018-07-31 2018-07-31
PCT/US2018/060699 WO2019094916A1 (en) 2017-11-13 2018-11-13 Methods and compositions for treating cancer by modifying multiple arms of the immune system

Publications (1)

Publication Number Publication Date
MX2020004914A true MX2020004914A (es) 2020-10-28

Family

ID=66439031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004914A MX2020004914A (es) 2017-11-13 2018-11-13 Metodos y composiciones para tratar el cancer mediante la modificacion de multiples brazos del sistema inmunitario.

Country Status (8)

Country Link
US (1) US20200317784A1 (es)
EP (1) EP3710035A4 (es)
JP (1) JP2021502423A (es)
AU (1) AU2018364752A1 (es)
BR (1) BR112020009363A2 (es)
CA (1) CA3082117A1 (es)
MX (1) MX2020004914A (es)
WO (1) WO2019094916A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US11246906B2 (en) 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
WO2021074689A1 (en) * 2019-10-18 2021-04-22 Alkermes Pharma Ireland Limited Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors
US20220370563A1 (en) * 2019-10-25 2022-11-24 Neoleukin Therapeutics, Inc. Methods of administration of il-2 receptor agonists
AU2020414355A1 (en) * 2019-12-24 2022-08-11 Neoleukin Therapeutics, Inc. Combination therapy using an IL-2 receptor agonist and an immune checkpoint inhibitor
WO2021202923A1 (en) * 2020-04-02 2021-10-07 Nektar Therapeutics Immunomodulator for the prevention and treatment of coronovirus infection and other conditions
KR102986821B1 (ko) * 2020-04-22 2026-07-06 머크 샤프 앤드 돔 엘엘씨 인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체
US20220257759A1 (en) * 2021-02-17 2022-08-18 Bioxcel Therapeutics, Inc. Treatment of sarcoma using immunomodulation
WO2024097856A1 (en) * 2022-11-03 2024-05-10 Onkosxcel Therapeutics, Llc Predictive biomarkers for responsiveness to dpp inhibitors in cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058957A2 (en) * 2005-11-10 2007-05-24 Point Therapeutics, Inc Boroproline compound and cytokine combination therapy
EA035259B1 (ru) * 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
PT3134123T (pt) * 2014-02-21 2021-03-22 Nektar Therapeutics India Pvt Ltd Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
CN108289912A (zh) * 2015-09-01 2018-07-17 先天肿瘤免疫公司 具有提高的免疫力或免疫抑制性细胞因子抗性的免疫细胞及其用途
EP3400291B2 (en) * 2016-01-08 2024-02-28 Replimune Limited Engineered virus

Also Published As

Publication number Publication date
AU2018364752A1 (en) 2020-05-28
JP2021502423A (ja) 2021-01-28
EP3710035A1 (en) 2020-09-23
WO2019094916A1 (en) 2019-05-16
BR112020009363A2 (pt) 2020-10-27
US20200317784A1 (en) 2020-10-08
EP3710035A4 (en) 2021-12-29
CA3082117A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
PH12016501978A1 (en) Treatment of nafld and nash
CO2017007671A2 (es) Composiciones para modular la expresión de c9orf72
MY190034A (en) Method of treating cancer associated with a ras mutation
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
MX2017004708A (es) Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control.
MX393612B (es) Vacuna contra viruela para tratamiento del cancer.
MX389560B (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
MX383484B (es) Método para tratar el cáncer.
EP4523744A3 (en) Treatment of cholestatic pruritus
MX384240B (es) Bacterias probioticas recombinantes.
MY194341A (en) Method of treating a brain tumor
EP4552698A3 (en) Methods of treating prostate cancer
BR112017018620A2 (pt) método de administração de tradipitanto, e, tradipitanto.
CL2019001002A1 (es) Métodos y composiciones para inmunoterapia por tusc2.
TW201613587A (en) Medical treatments based on anamorelin
PH12016501769B1 (en) Treatment of intrahepatic cholestatic diseases
MX2018012230A (es) Métodos para tratar enfermedades oculares.
PH12017500602A1 (en) Methods for treating ocular conditions
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
GB2553439A (en) Methods for scoring chromosomal instabilities